NewsRSSYesterday
This is a personal story about a man with ALS (a disease that affects nerve cells and causes muscle weakness) and how his dog Comet has become an important part of his life. As Todd's mobility has decreased over time, he's found creative ways to spend time with Comet, like riding on a scooter with the dog. The story shows how pets can bring joy and connection to people living with serious illnesses.
WHY IT MATTERSFor people with ALS and their caregivers, this story demonstrates how adaptive strategies and pet companionship can maintain quality of life and emotional well-being as the disease progresses.
ResearchRSS3 days ago
A new study from Denmark found that people with higher levels of HCB (a pesticide that was banned in many countries) in their blood may have a higher risk of developing ALS, a disease that affects nerve cells and causes muscle weakness. HCB was used as a pesticide in the past but is no longer allowed in many places because it can be harmful to health. This research suggests that exposure to this old pollutant might be connected to ALS risk.
WHY IT MATTERSIf you have ALS or a family history of it, understanding environmental risk factors like HCB exposure could help you and your doctor identify potential causes and discuss ways to reduce exposure to similar pollutants.
ResearchRSS3 days ago
Scientists studied how spinal muscular atrophy (SMA) damages the connections between nerves and muscles. They found that in people with SMA, these nerve-muscle connections don't develop properly right after birth, making them weak and unable to work well before nerve cells start dying. This early problem may be an important part of how SMA causes muscle weakness.
WHY IT MATTERSUnderstanding that nerve-muscle connection problems happen early in SMA—before nerve cell loss—could lead to new treatments that target this early stage rather than only treating later damage.
ResearchCLINICALTRIALSMar 26
Researchers are studying how doctors treat a rare muscle weakness disease called generalized myasthenia gravis (gMG) in Russia. They want to understand what treatments work best in real-world practice by following 450 patients over time. This study is not testing a new drug, but rather collecting information about treatments that are already being used.
WHY IT MATTERSIf you have AChR-antibody positive generalized myasthenia gravis in Russia, this study could help doctors understand which current treatment approaches work best for patients like you in your region.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called S-606001 to see if it can help adults with late-onset Pompe disease when added to their current enzyme replacement therapy (ERT) treatment. Pompe disease is a rare genetic condition where the body can't break down a type of sugar, causing muscle weakness over time. This study will check if the new drug is safe and if it helps patients feel better or move more easily. The trial is currently looking for 45 adult participants to join.
WHY IT MATTERSThis trial is actively recruiting adults with late-onset Pompe disease who are already on enzyme replacement therapy — eligible participants may be able to access an investigational add-on treatment that could potentially improve their muscle function.